Anti-Human TACE Ectodomain (Clone 111623)
Code | Size | Price |
---|
LEI-T461-25ug | 25 ug | £375.00 |
Quantity:
LEI-T461-500ug | 500 ug | £785.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG1
Antibody Clonality: Monoclonal
Antibody Clone: 111623
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunoprecipitation (IP)
- Western Blot (WB)
Shipping:
Ambient
Storage:
The lyophilized antibody can be stored desiccated at -20°C to -70°C for up to twelve months. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid repeated freeze thaw cycles. No detectable loss of activity was observed after six months.
Further Information
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This monoclonal antibody has been 0.2 um filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 7.2 - 7.3 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present.
Formulation:
This monoclonal antibody has been 0.2 um filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 7.2 - 7.3 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present.
Immunogen:
T. ni Cell-Derived Recombinant Human TACE (Accession # P78536)
Long Description:
TACE (tumor necrosis factor-α-converting enzyme) is a pleiotropic metalloprotease also known as ADAM17 that is found to be constitutively expressed by intestinal epithelial cells.1 TACE is a major sheddase of TNF-α and its receptors, essential for the generation of soluble, mature molecules.2 TACE as a promising target of epidermal growth factor receptor (EGFR) axis inhibition in colorectal cancer (CRC)3 and a principal target for the treatment of TNF-dependent pathologies.4
NCBI Gene:
6868
Target:
TACE Ectodomain
References
1. Masson, D. et al. (2009) Int J Mol Med. 23: 41
2. Chodynicka, B. et al. (2008) J European Acad Dermatol & Venereol. 22: 712
3. Coffey, RJ. et al. (2008) Clin Cancer Res. 14: 1182
4. Blobel, CP. et al. (2007) J Immunol. 179: 2689